8-K: GoodRx Stockholders Re-Elect Directors, Ratify Auditor, and Approve Executive Compensation at Annual Meeting

GoodRx Holdings, Inc. announced that its stockholders overwhelmingly approved all proposals at the Annual Meeting held on June 3, 2025, including the re-election of three Class II directors, the ratification of PricewaterhouseCoopers LLP as its independent auditor, and the advisory approval of executive compensation.

Summary

• GoodRx Holdings, Inc. held its Annual Meeting of Stockholders on June 3, 2025.
• As of the Record Date of April 9, 2025, holders of Class A common stock were entitled to one vote per share, and Class B common stock holders were entitled to ten votes per share.
• A total of 89,529,900 shares of Class A common stock and 256,869,320 shares of Class B common stock were present or represented by proxy, accounting for approximately 99.5% of the combined voting power.
• Stockholders elected Christopher Adams, Trevor Bezdek, and Scott Wagner as Class II directors for a term expiring at the 2028 Annual Meeting.
• The appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
• The compensation of the company's named executive officers was approved on an advisory (non-binding) basis.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as all proposals presented at the Annual Meeting passed with overwhelming shareholder approval, indicating strong confidence in the company's governance, management, and strategic direction. There were no contentious votes or unexpected outcomes.

Positives

• All three Class II directors (Christopher Adams, Trevor Bezdek, and Scott Wagner) were successfully re-elected with overwhelming shareholder support, indicating stability in the board.
• The appointment of PricewaterhouseCoopers LLP as the independent auditor was ratified with strong approval, reflecting confidence in the company's financial oversight.
• The advisory vote on executive compensation passed with significant shareholder approval, suggesting alignment between executive pay and shareholder interests.
• A high percentage of voting power (approximately 99.5%) was represented at the meeting, indicating strong shareholder engagement.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding future financial performance or strategic initiatives, focusing solely on the outcomes of the annual stockholder meeting.

Industry Context

This filing pertains to routine corporate governance matters for GoodRx Holdings, Inc. and does not provide specific insights into broader industry trends or competitive dynamics within the healthcare technology or pharmaceutical discount sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: The successful election of directors and approval of key proposals indicates stability and continuity in corporate governance, potentially reinforcing investor confidence.
• Management: The advisory approval of executive compensation suggests shareholder alignment with the current pay structure, which can positively impact management morale and focus.
• Employees: Stable corporate governance and clear direction from the board can contribute to a more secure and focused work environment.

Key Dates

Recommendation

Keywords

GoodRx, GDRX, Annual Meeting, Stockholders, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, 8-K, Healthcare Technology, Pharmacy Discounts